Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells

Anti-Cancer Drugs

Volumn 16, Issue 3, 2005, Pages 285-292

  Temmink, Olaf H ^a   De Bruin, Michiel ^a   Comijn, Elizabeth M ^a   Fukushima, Masakazu ^b   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Antifolate; DNA incorporation; Thymidine phosphorylase; Thymidylate synthase; Time dependent pharmacologic effect; Trifluorothymidine

Indexed keywords

5 FLUORO 2' DEOXYTHYMIDINE; FLOXURIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GLYCOSYLTRANSFERASE INHIBITOR; TAS 102; THYMIDINE DERIVATIVE; THYMIDINE PHOSPHORYLASE; THYMIDINE PHOSPHORYLASE INHIBITOR; THYMIDYLATE SYNTHASE; TRIFLURIDINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG UPTAKE; ENZYMATIC DEGRADATION; ENZYME DEFICIENCY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THIN LAYER CHROMATOGRAPHY; TUMOR GROWTH;

ANTIMETABOLITES; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DNA; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRIFLURIDINE; TUMOR CELLS, CULTURED;

EID: 14144256008     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200503000-00007     Document Type: Article

References (44)

1. Carreras CW, Santis DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995; 64:721-762.
2. van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57:179-194.
3. Danenberg PV, Malli H, Swenson S. Thymidylate synthase inhibitors. Semin Oncol 1999; 26:621-631.
4. Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995; 6:871-881.
5. Pinedo HM, Peters GJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6:1653-1664.
6. Berger SH, Berger FG. Thymidylate synthase as a determinant of 5-fluoro-2′-deoxyuridine response in human colonic tumor cell lines. Mol Pharmacol 1988; 34:474-479.
7. Santi DV, Sakai TT. Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2′-deoxyuridylic acid. Biochemistry 1971; 10:3598-3607.
8. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587:194-205.
9. Eckstein JW, Foster PG, Finer-Moore J, Wataya Y, Santi DV. Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)- 2′-deoxyuridine 5′-monophosphate. Biochemistry 1994; 33:15086-15094.
10. Santi DV, Sakai TT. Irreversible inhibition of thymidylate synthetase by 5-formyl-2′-deoxyuridylic acid. Biochem Biophys Res Commun 1972; 46:1320-1325.
11. Aherne GW, Hardcastle A, Raynaud F, Jackman AL. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 1996; 51:1293-1301.
12. Caradonna SJ, Cheng YC. The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells. Mol Pharmacol 1980; 18:513-520.
13. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002; 28:27-47.
14. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998; 82:70-77.
15. Peters GJ, van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994; 12:2035-2042.
16. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995; 49:1419-1426.
17. Inaba M, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimon A, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996; 87:212-220.
18. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52:1855-1864.
19. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000; 17:277-283.
20. Ackland SP, Peters GJ. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Update 1999; 2:205-214.
21. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92:998-1002.
22. De Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003; 88:957-964.
23. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 2000; 59:1227-1236.
24. Ansfield FJ, Ramirez G. Phase I and II studies of 2′-deoxy-5- (trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 1971; 55:205-208.
25. Takao S, Akiyama SI, Nakajo A, Yoh H, Kitazono M, Natsugoe S, et al. Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res 2000; 60:5345-5348.
26. Thomas MB, Hoff PM, Carter S, Bland G, Lassere Y, Wolff R, et al. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/antiangiogenic agent given orally on a once-daily schedule for five days every three weeks in patients with solid tumors. Proc Am Ass Cancer Res 2002; 43:554 (abstr 2754).
27. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992; 52:4306-4312.
28. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003; 66:431-438.
29. van der Wilt CL, Cloos J, De Jong M, Pinedo HM, Peters GJ. Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. Oncol Res 1995; 7:317-321.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
31. Keepers YP, Pizao PE, Peters GJ, Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991; 27:897-900.
32. Peters GJ, Wets M, Keepers YP, Oskam R, Ark-Otte J, Noordhuis P, et al. Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 1993; 54:450-455.
33. Rots MG, Pieters R, Kaspers GJ, van Zantwijk CH, Noordhuis P, Mauritz R, et al. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 1999;93:1067-1074.
34. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5- fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46:20-28.
35. Laurensse EJ, Pinedo HM, Peters GJ. A sensitive non-radioactive assay for pyrimidine nucleoside phosphorylase using reversed-phase high performance liquid chromatography. Clin Chim Acta 1988; 178:71-78.
36. van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000; 6:1063-1072.
37. Peters GJ, Laurensse E, Lankelma J, Leyva A, Pinedo HM. Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. Eur J Cancer Clin Oncol 1984; 20:1425-1431.
38. Temmink OH, Comijn EM, Fukushima M, Peters GJ. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides, Nucleotides and Nucleic Acids 2004; 23:1491-1494.
39. Patterson AV, Talbot DC, Stratford IJ, Harris AL. Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro. Cancer Res 1998; 58:2737-2740.
40. Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol Rep 2004; 11:381-387.
41. Elkouni MH, Elkouni MM, Naguib FNM. Differences in activities and substrate-specificity of human and murine pyrimidine nucleoside phosphorylases - implications for chemotherapy with 5-fluoropyrimidines. Cancer Res 1993; 53:3687-3693.
42. Eriksson S, Kierdaszuk B, Munchpetersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase-1 and kinase-2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991; 176:586-592.
43. Matsumura M, Chiba Y, Lu C, Amaya H, Shimomatsuya T, Horiuchi T, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett 1998; 128:55-63.
44. Emura T, Nakagawa F, Fujioka A, Ohshimo H, Yokogawa T, Okabe H, Kitazato K. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004; 13:249-255.